Provenance Record

FDA RTCT pilot announcement, primary-sourced via fda.gov + GlobeNewswire FDA distribution + BioPharma Dive. All quoted material verbatim.

{"https://www.fda.gov/news-events/press-announcements/fda-announces-major-steps-implement-real-time-clinical-trials":"source-0.html — primary FDA press release. All claims verified: AstraZeneca TRAVERSE Phase 2 mantle cell lymphoma trial with MD Anderson + UPenn, Amgen STREAM-SCLC Phase 1b small cell lung carcinoma trial with site selection in process, Makary 'For 60 years, we've been conducting clinical trials in the same way' quote verbatim, 'in real time as a trial progresses' verbatim, 'real-time, continuous trials across all phases of drug development' verbatim, May 29 RFI deadline, July selection criteria publication, August pilot selections.","https://www.globenewswire.com/news-release/2026/04/28/3283099/0/en/FDA-Announces-Major-Steps-to-Implement-Real-Time-Clinical-Trials.html":"source-2.html — same FDA press release distributed via GlobeNewswire. Identical content to source-0; the article uses this URL for inline links because it's allowlisted while fda.gov direct may not be.","https://www.biopharmadive.com/news/fda-real-time-trials-abbvie-kestrel-lilly-profluent/818719/":"source-1.html — corroborates the AstraZeneca + Amgen partnership and the FDA's stated objective of compressing review-decision lag time."}

All claims verified verbatim against the FDA primary source. The article omits the Amgen trial's name (STREAM-SCLC, mentioned in FDA release) but doesn't misattribute anything.

APPROVE. Primary-sourced, well-attributed, conservative framing.